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GLOSSARY
1D = 1-dimensional; AASM = American Academy of Sleep Medicine; AUC = area under the receiver 
operator characteristic curve; CI = confidence interval; CNN = convolutional neural networks; DL = 
deep learning; EEG = electroencephalogram; ICU = intensive care unit; LSTM = long short-term 
memory; MOAA/S = Modified Observer’s Assessment of Alertness/Sedation Scale; NREM = nonr-
apid eye movement; ReLU = rectified linear unit; REM = rapid eye movement; R&K = Rechtschaffen 
and Kales; SHHS = Sleep Heart Health Study; TW = time-bandwidth product; UMCG = University 
Medical Center Groningen
KEY POINTS
• Question: Because anesthetic drugs exhibit sleep-like patterns during deep hypnosis, can we 
predict hypnosis level from sleep brain rhythms?
• Findings: Deep learning algorithms when trained on nonrapid eye movement stage 3 sleep 
electroencephalogram can predict dexmedetomidine-induced deep hypnotic level.
• Meaning: Anesthetic-induced hypnosis levels can be predicted using sleep electroencepha-
logram and artificial intelligence techniques, eliminating the need for clinical trials to develop 
hypnotic level monitors.
BACKGROUND: Brain monitors tracking quantitative brain activities from electroencephalogram 
(EEG) to predict hypnotic levels have been proposed as a labor-saving alternative to behavioral 
assessments. Expensive clinical trials are required to validate any newly developed processed 
EEG monitor for every drug and combinations of drugs due to drug-specific EEG patterns. There 
is a need for an alternative, efficient, and economical method.
METHODS: Using deep learning algorithms, we developed a novel data-repurposing framework 
to predict hypnotic levels from sleep brain rhythms. We used an online large sleep data set 
(5723 clinical EEGs) for training the deep learning algorithm and a clinical trial hypnotic data 
set (30 EEGs) for testing during dexmedetomidine infusion. Model performance was evaluated 
using accuracy and the area under the receiver operator characteristic curve (AUC).
RESULTS: The deep learning model (a combination of a convolutional neural network and long 
short-term memory units) trained on sleep EEG predicted deep hypnotic level with an accuracy 
(95% confidence interval [CI]) = 81 (79.2–88.3)%, AUC (95% CI) = 0.89 (0.82–0.94) using 
dexmedetomidine as a prototype drug. We also demonstrate that EEG patterns during dexme-
detomidine-induced deep hypnotic level are homologous to nonrapid eye movement stage 3 
EEG sleep.
CONCLUSIONS: We propose a novel method to develop hypnotic level monitors using large 
sleep EEG data, deep learning, and a data-repurposing approach, and for optimizing such a 
system for monitoring any given individual. We provide a novel data-repurposing framework to 
predict hypnosis levels using sleep EEG, eliminating the need for new clinical trials to develop 
hypnosis level monitors.  (Anesth Analg 2020;130:1211–21)
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Current practice for monitoring the hypnotic component of anesthesia relies mainly on intermittently obtained patient’s response to 
a verbal and/or tactile stimulus.1 Brain monitors that 
track quantitative electroencephalogram (EEG) sig-
natures to monitor anesthesia have been proposed 
as an alternative to clinical hypnosis assessments.2,3 
Although they have widespread use in clinical prac-
tice, their performance is limited (lack of consistency 
and reliability) and is drug-specific.2–4 One main 
reason for such limited performance is that these 
monitors are developed using a small data set from 
controlled clinical trials using specific drugs and do 
not capture large heterogeneity between patients. 
In addition, expensive clinical trials are required to 
develop and/or validate any newly developed pro-
cessed EEG monitor for every drug and combinations 
of drugs due to drug-specific EEG patterns.
In recent years, large publicly available heteroge-
neous expert labeled data sets have provided several 
benefits for developing clinical decision tools using 
deep learning (DL) algorithms. One such applica-
tion is EEG-based sleep scoring systems where the 
DL algorithm is trained to automatically score 5 
sleep stages and have already reached expert-level 
performance.5–7 Recent clinical studies suggest that 
anesthetic drugs also induce specific sleep-like EEG 
patterns at different levels of hypnosis.8 For example, 
propofol induces slow waves in EEG at deep hyp-
notic levels resembling slow waves of nonrapid eye 
movement (NREM) sleep EEG9; dexmedetomidine 
approximates NREM sleep with slow waves and 
spindle-like patterns in the EEG during deep hyp-
notic state.10–13
Motivated by numerous studies demonstrating 
sleep-like inhibition of anesthetic drugs, and major 
breakthroughs in the application of DL algorithms 
for hypnosis monitoring14–16 and sleep staging5–7 
using EEG, we propose a novel data-repurposing 
framework to predict Anesthesia-induced hypnotic 
levels from sleep EEG using DL in this study. DL 
algorithms learn patterns directly from the raw EEG 
data eliminating the necessity to extract hand-crafted 
engineering features from EEG for prediction. We 
demonstrate this framework by using dexmedeto-
midine as a prototype drug. We train the DL algo-
rithm on a publicly available sleep EEG data set 
(5723 subjects) to predict different levels of hypnosis 
on the independent dexmedetomidine clinical trial 
EEG data set (30 subjects). We hypothesized that the 
DL model trained on sleep data set should be able 
to track dexmedetomidine-induced hypnosis. This 
will enable the development of a clinical EEG moni-
tor with much broader application possibilities with-
out the need for validating every drug-induced EEG 
change with a clinical trial.
METHODS
Data Set
EEG recordings used in this study were obtained from 
2 different sources: A dexmedetomidine clinical study 
data set (N = 30, mean age: 40.7 ± 15.8 years, male = 
15, female = 15) from The University Medical Center 
Groningen (UMCG) and the publicly available Sleep 
Heart Health Study (SHHS) data set (N = 5723, mean 
age: 63.1 ± 11.2 years, male = 2728, female = 2993).17–20 
The dexmedetomidine clinical trial was conducted in 
accordance with the Declaration of Helsinki and appli-
cable good clinical practice and regulatory require-
ments. The study had ethical approval from the “The 
Independent Ethics Committee” (Medisch Ethische 
Toetsings Commissie) of the Foundation “Evaluation 
of Ethics in Biomedical Research” (Stichting BEBO), 
Assen, the Netherlands. The dexmedetomidine clini-
cal trial study was registered before patient enrollment 
at Clinical Trials.gov (Identifier: NCT03143972, princi-
pal investigator: Michel M. R. F. Struys, date of regis-
tration: June 28, 2017). Informed written consent was 
obtained from all volunteers before EEG recordings. 
Permission to use the SHHS data set was obtained 
from the online portal: www.sleepdata.org. A detailed 
description of UMCG dexmedetomidine data set and 
experimental protocol can be found elsewhere.21
The levels of hypnosis in the UMCG data set were 
scored by 3 expert anesthesiologists using the Modified 
Observer’s Assessment of Alertness/Sedation 
(MOAA/S) score.22 MOAA/S scores denote 6 levels of 
hypnosis ranging from 5 (responding readily to name 
spoken in normal tone) to 0 (not responding to a pain-
ful trapezius squeeze/deep hypnotic state). The initial 
sleep scores of SHHS data set (using the Rechtschaffen 
and Kales [R&K] guidelines23) were converted to the 
American Academy of Sleep Medicine (AASM) guide-
lines24 by combining NREM stages 3 and 4 as single 
NREM stage 3: wake (W), NREM sleep: stages 1 (N1), 2 
(N2), and 3 (N3), and rapid eye movement (REM)—R. 
EEG recordings with <5 sleep stages in SHHS data set 
were excluded from the analysis, resulting in a total of 
5723 EEG recordings (initial SHHS data set consisted 
of 5804 EEG recordings). We excluded EEG record-
ings with <5 sleep stages to remove patients with 
severe sleep disorders. Sleep stage scoring was not 
performed in the UMCG data set because the goal of 
this study was not to develop another automatic sleep 
scoring system but to develop a framework predict-
ing dexmedetomidine-induced hypnosis levels using 
sleep EEG. A priori power analysis was not performed 
to guide sample size in data collection.
EEG Recordings
The UMCG data set consisted of 17 channel scalp 
EEG (Fp1, Fp2, F3, Fz, F4, T7, C3, Cz, C4, T8, P3, Pz, 
P4, O1, O2, A1, A2) and SHHS data set had 2 central 
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EEG channels: primary (C4/A1) and secondary (C3/
A2). EEG recordings from subjects in UMCG data 
set were collected using BrainAmp DC32 amplifier 
with a BrainVision recorder at a sampling frequency 
of 5 kHz. For the entire study duration, subjects were 
instructed to close their eyes. Subjects with neurologi-
cal/cardiovascular/pulmonary/gastric/endocrino-
logical disorders, history of psychoactive medications 
usage, >20 g/d alcohol consumption, or pregnancy 
were not included in the study.
Dexmedetomidine was administered in a step-
up dosing regimen by using the effect-site target-
controlled infusion using the Hannivoort-Colin 
model.25,26 First, 5-minute baseline data were 
obtained in which subjects were asked to relax and 
close their eyes. Later, dexmedetomidine was admin-
istered using the following effect-site target concen-
tration: 1, 2, 3, 5, 8 ng/mL for 40 (0–40), 50 (40–90), 
40 (90–130), 40 (130– 70), and 50 (170–220) minutes, 
respectively. This dosage regimen allowed all effect 
sites to reach a steady state. Dexmedetomidine 
infusion was ceased after the 220th minute. The 
MOAA/S assessment was performed at baseline, at 
each infusion step, and during the recovery phase 
after cessation. In addition, before each increase in 
infusion step, laryngoscopy was performed if the 
MOAA/S score was <2. Except for the MOAA/S 
assessments, volunteers were not stimulated and 
ambient noise was kept low throughout the study 
session. Figure  1 shows the behavioral response 
(MOAA/S scores) and the corresponding EEG spec-
trogram of a subject from the UMCG data set. More 
details about the dexmedetomidine data set can be 
found in Weerink et al.21
EEG Preprocessing and Epoch Extraction
For the present study, we used 2 EEG channels com-
mon to UMCG and SHHS data set: C4/A1 and C3/
A2. We first bandpass filtered the EEG signals between 
0.5 and 30 Hz and then downsampled to 125 Hz (to 
match SHHS data set sampling frequency). To reduce 
the impact of differences in the amplifiers during EEG 
acquisition (which may have significantly affected the 
amplitude of the EEG signals), we standardized the 
EEG to have zero median and unit interquartile range 
for the entire recording in both data sets. We restricted 
the upper-frequency range to 30 Hz to eliminate the 
majority of muscle artifacts during the awake state. 
The EEG data were divided into nonoverlapping 
30-second segments resulting in a total of 5,767,772 
and 10,528 segments in SHHS and UMCG data set, 
respectively. Supplemental Digital Content, Figure 
1, http://links.lww.com/AA/D7, shows the distri-
bution of 30-second segments in different classes for 
both data sets.
DL Architecture
We used LSTM-CNN architecture: a combination of a 
convolutional neural network (CNN) and long short-
term memory units (LSTM), which was recently used 
for EEG-based expert-level sleep stage scoring5 as 
shown in Figure 2 to predict levels of hypnosis. The 
CNN module extracts discriminative features from 
the raw EEG, and the LSTM module captures tem-
poral dynamics in the EEG. To obtain the probabil-
ity score, we used a final dense layer with sigmoid 
activation. We used glorot uniform initializer to ini-
tialize the weights of the neural network and trained 
the LSTM-CNN from scratch. To avoid overfitting, 
we used L2 weight regularization and the model was 
Figure 1. Sample dexmedetomidine 
data. Illustration of (A) 15 s sample 
EEG at minute 5 and minute 108, (B) 
C4/A1 channel EEG spectrogram, 
and (C) MOAA/S score of a subject 
from UMCG data set and red-dotted 
line shows target-controlled infu-
sion of dexmedetomidine in nano-
gram per milliliter. We can see the 
presence of spindle waves with an 
increase in the level of hypnosis. The 
following values were set to perform 
spectral estimation using multitaper 
spectral estimation via the chronux 
toolbox: length of the window T = 4 s 
with 0.1 s shift, time-bandwidth prod-
uct TW = 3, number of tapers K = 5, 
and spectral resolution 2 W of 1.5 
Hz. EEG indicates electroencephalo-
gram; MOAA/S, Modified Observer’s 
Assessment of Alertness/Sedation 
Scale; TW, time-bandwidth product.
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trained using the stochastic gradient descent algo-
rithm (learning rate = 0.01, momentum = 0.9, weight 
decay = 0.0001), and binary cross-entropy as a loss 
function. This architecture demonstrated to perform 
expert-level sleep scoring using large-scale sleep EEG 
data with rigorous hyper-parameter tuning similar to 
the architecture used in Biswal et al.5 All experiments 
were performed on a local computer with Intel Xeon 
4116, 32GB RAM, NVidia 1080Ti GPU, and CUDA 9.0. 
LSTM-CNN models were implemented using Keras 
wrapper with Tensorflow 2.0 backend in Python 
scripting language.
Training and Testing
To identify which sleep stage predicts different 
levels of hypnosis induced by the dexmedetomi-
dine infusion, we performed the following binary 
classifications:
 1. Label awake stage as 0 and sleep stage as 1, that 
is, W = 0, N1 = 1 in SHHS data set (denoted 
as WN1). Similarly, label awake state as 0 and 
hypnotic state as 1, that is, MOAA/S score 5 = 
0, MOAA/S score 4 = 1 in the UMCG data set 
(denoted as M54).
Figure 2. The architecture of the LSTM-CNN model5 used in this study. The length of the input 1D EEG segment is 125 (samples) × 30 (sec-
onds). The output of the model provides a probability score of a given EEG segment belonging to deep hypnotic state. “x4” refers to number 
of layers of residual network. In this architecture there are 4 + 4 + 4 = 12 layers of residual network. 1D indicates 1-dimensional; CNN, con-
volutional neural networks; EEG, electroencephalogram; LSTM, long short-term memory; ReLU, rectified linear unit.
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 2. Balance the data using undersampling group 
equalization strategy (select random epochs 
from both groups corresponding to the length 
of minority group) to set random chance level 
prediction accuracy to 50% in both data sets.
 3. Train the LSTM-CNN model on WN1.
 4. Predict the probability of hypnotic level in M54 
using the trained model.
 5. Repeat steps 1–3 until all MOAA/S states are 
used for prediction in step 4 (M53, M52, M51, 
M50).
 6. Repeat steps 1–5 until all sleep stages are used 
for training (WN2, WN3, WR).
This process is illustrated in Figure 3. We performed 
a binary classification instead of multiclass prediction 
for 2 reasons. First, the primary goal of this study was 
to identify which individual sleep stage corresponded 
to a different level of MOAA/S score and not to pre-
dict 6 levels of MOAA/S scores from 5 sleep stages. 
Training the model to track different levels of hypnosis 
of sedation based on varying stages of sleep is not ideal 
because the annotation systems are different in the 2 
data sets. Second, a multiclass prediction model will 
again result in discrete hypnotic level scores. Because 
hypnotic level is continuous, it is desirable to obtain 
a continuous score and we achieved this by means of 
probabilistic estimation using a sigmoid layer.
We fixed the batch size to 500 and numbers of 
epochs to 100 for model training, which means that 
the training data were provided 100 times to the 
network in chunks of 500 segments. We used 90% 
of the SHHS data (5150 patients) for training LSTM-
CNN model and 10% (573 patients) for validation, 
and the UMCG data were held out as a completely 
independent test set. Since multiple EEG segments 
from the same patient were included in the analysis, 
we ensured that the EEG segments in both sets were 
independent, that is, no overlap of patients in training 
and validation sets. Model training was terminated if 
(1) the validation accuracy reached 100%, or (2) fin-
ished 100 epochs, or (3) no change in the loss function 
of the validation set. After training, from each trained 
model, we predicted the hypnosis level on the UMCG 
data set. The accuracy and the Yp of the awake or hyp-
notic state of the EEG segment were estimated. Here, 
YpYp = 1 and Yp = 0Yp  corresponds to deep hypnotic 
and awake states, respectively. The classification was 
performed separately for 2 channels.
Internal Cross-Validation
To evaluate how well LSTM-CNN model performs 
when trained and tested on the same data, we also 
performed internal 5-fold cross-validation, that is, 
trained and tested the model within same data (train 
and test on SHHS data; train and test on UMCG data) 
when compared to trained on one data (SHHS) and 
tested on other (UMCG).
Continuous Hypnotic Level Assessment
Because hypnosis level is continuous, it is important 
to obtain a continuous probabilistic estimation of level 
of hypnosis. The proposed framework in this study 
raises an important question: given the output of the 
sleep stage prediction model, which MOAA/S score 
does the model predict for a new EEG segment? To 
obtain a continuous level of hypnosis, we performed 
the following: for each subject, we predicted all levels 
of MOAA/S scores using the best performing sleep 
model to assign probability score to each 30-sec-
ond EEG epoch. By this way, we map discrete levels 
MOAA/S scores to continuous probability scores as 
shown in Figure  4A. As the probability score → 1, 
the subject enters into deep hypnotic state. We then 
Figure 3. Illustration of the training testing experiment performed in this study. Because there are 4 sleep stages (N1, N2, N3, R) and a 
wake stage (W), we trained 4 separate DL models for binary classification: WN1, trained on W and N1; WN2, trained on W and N2; WN3, 
trained on W and N3; and WR, trained on W and R. Each model was then used to differentiate between awake (MOAA/S = 5) and individual 
dexmedetomidine-induced hypnotic levels. For example, WN1 was used to differentiate between MOAA/S = 5 and 4 (M54), MOAA/S = 5 and 3 
(M53), and so on until MOAA/S = 5 and 0 (M50) to estimate the probability of hypnosis YpYp. This process was repeated until all sleep stage 
DL models were used for predicting hypnosis levels. DL indicates deep learning; MOAA/S, Modified Observer’s Assessment of Alertness/
Sedation Scale; UMCG, University Medical Center Groningen.
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estimated a Spearman rank correlation (ρ) between 
different level of MOAA/S scores and WN3 model 
probability output.
Spectrogram Analysis
To compare the performance of LSTM-CNN model 
with traditional spectrogram analysis, we estimated 
5 spectral features from each 30-second EEG segment 
in the UMCG data set: delta (0.5–4 Hz), theta (4–8 Hz), 
alpha (8–12 Hz), spindle (12–16 Hz), and beta (16–30 
Hz) power in decibel scale. Spectral estimation was 
performed using the Thompson multitaper spectral 
estimation method via chronux toolbox27 with the 
following parameters: length of the window T = 4 sec-
onds with 0.1-second shift (3.9 seconds overlap), time-
bandwidth product time-bandwidth product (TW) = 
3, number of tapers K = 5, and spectral resolution 2 W 
of 1.5 Hz.
Evaluation Metrics
We used the overall classification accuracy to evaluate 
the performance of the LSTM-CNN algorithm. We also 
report the area under the receiver operator characteris-
tic curve (AUC). All results are reported as mean (95% 
confidence interval [CI]) unless otherwise stated. The 
Figure 4. Hypnosis level prediction out-
put. A, Illustration of mapping discrete 
MOAA/S score onto a continuous prob-
ability score via sigmoid transforma-
tion. Here probability score = 0 and 1 
correspond to awake and deep hypnotic 
state, respectively. B, Illustration of 
correlation (ρ = 0.53 in this example) 
between the probability score predicted 
by the DL model (blue) and MOAA/S 
scores (red), and (C) box plot compar-
ing the distribution of predicted proba-
bility scores across all MOAA/S scores. 
Here the probability score is obtained 
by the WN3 LSTM-CNN model tested 
on all MOAA/S scores. The predicted 
probability score tends toward zero with 
increase in level of consciousness. 
Here the DL model is trained on wake 
and NREM stage 3 EEG segments and 
is used to predict all levels of MOAA/S 
scores (MOAA/S 0, 1, 2, 3, 4, 5) to 
obtain continuous levels of hypnosis. 
CNN indicates convolutional neural net-
works; DL, deep learning; EEG, electro-
encephalogram; LSTM, long short-term 
memory; MOAA/S, Modified Observer’s 
Assessment of Alertness/Sedation 
Scale; NREM, nonrapid eye movement.
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95% CI was estimated using bootstrapping with 1000 
samplings (BCa method) on the test data set.
RESULTS
Cross–Data Set Experiment
The Table summarizes the prediction performance of 
the LSTM-CNN model when trained on individual 
sleep states to predict different levels of MOAA/S 
scores. The LSTM-CNN WN3 model (trained on 
W and N3 stage) achieved an accuracy = 81 (79.2–
88.3)%, AUC = 0.89 (0.82–0.94) in predicting dexme-
detomidine deep hypnotic state (in channel C4/A1) 
much better than the random chance level accuracy 
of 50%. The LSTM-CNN model discriminated W and 
N3 during training with an accuracy of 98% and 95% 
in the training and validation set, respectively. The 
performance was poor for other models suggesting 
that dexmedetomidine deep hypnotic state is analo-
gous to N3 sleep patterns. Similar performance was 
obtained in the secondary C3/A2 channel (accuracy 
= 81 [78.2–87.6]%, AUC = 0.88 [0.80–0.93]). Examples 
of EEG epochs and their corresponding predicted 
probabilities are shown in Supplemental Digital 
Content, Figure 2, http://links.lww.com/AA/D7. 
Supplemental Digital Content, Figure 3, http://
links.lww.com/AA/D7, shows the confusion matri-
ces for predicting M50 using individual sleep stages. 
Prediction performance for individual subjects is 
given in Supplemental Digital Content, Table 1, 
http://links.lww.com/AA/D7, and the performance 
on the raw data (without balancing the testing test) is 
summarized in Supplemental Digital Content, Table 
2, http://links.lww.com/AA/D7.
Internal Cross-Validation Within Each Data Set
To further evaluate the prediction performance of 
the LSTM-CNN model within each data set, we 
performed 5-fold cross-validation to discriminate 
between (1) W and N3 stage in the SHHS data set, 
and (2) awake (MOAA/S = 5) and deep hypnotic 
state (MOAA/S = 0) in the UMCG data set. The fol-
lowing performances were obtained: accuracy = 95.5 
(91.2–99.4)%, AUC = 0.98 (0.91–0.99), and accuracy = 
85.4 (79.3–89.6)%, AUC = 0.93 (0.89–0.96) for SHHS 
and UMCG data set (in channel C4/A1), respectively. 
Similarly, in the secondary channel (C3/A2), accu-
racy of 94.2 (90.8–99.1)% and AUC = 0.97 (0.90–0.99) 
in SHHS data set, and accuracy of 85.1 (78.5–88.7)% 
and AUC = 0.92 (0.87–0.95) in UMCG data sets were 
obtained. Because the training and testing were per-
formed within UMCG data set during cross-valida-
tion, there was a 4% increase in the prediction accuracy 
in UMCG data set when compared to the cross–data 
set prediction accuracy (85% vs 81%). However, this 
increase in accuracy was not significant (P = .764).
Continuous Hypnosis Level Estimation
Next, using WN3 model that was trained only using 
wake and N3 sleep stages, we predicted all MOAA/S 
scores for each subject. This resulted in a mean ρ = 
0.40 (0.34–0.78), suggesting that the proposed method 
can be useful in developing continuous hypnotic level 
prediction system. Intermediate probability scores 
will provide an estimate of the deep hypnotic level 
of a subject. An example illustrating this is shown in 
Figure 4B. Here, Yp = 0 indicates awake state (MOAA/S 
= 5) and Yp = 1 indicates deep hypnotic state. Yp = 0.6 
indicates that the probability of patient being in deep 
hypnotic state is 0.6 and the drug infusion should be 
increased to increase the level of hypnosis (or reach 
MOSS/S score 0). The distribution of all predicted 
probability scores versus MOAA/S scores is shown 
in Figure 4C. With a decrease in the level of hypnosis 
(or increasing MOAA/S scores), the predicted prob-
ability score tends toward zero. Though promising, 
the proposed mapping method needs to be further 
validated/tested in another external data set.
Comparison With Spectral Analysis
To evaluate the performance of individual spec-
tral features, we performed a binary classification 
between 2 extreme levels of hypnosis: MOAA/S = 5 
and MOAA/S = 0. The following prediction accura-
cies were obtained using individual spectral features: 
delta power = 54.4 (51.3–58.4)%, theta power = 50.6 
(45.2–55.3)%, alpha power = 51.3 (44.2–57.5)%, spindle 
Table. Performance (Accuracy [95% CI]) of the LSTM-CNN Model Trained on Individual Sleep Stages to 
Predict Different Levels of MOAA/S Scores
Testing Training M54 M53 M52 M51 M50
WN1 51.2 (45.3–54.4) 46.5 (41.2–51.3) 46.3 (41.5–52.4) 40.4 (35.4–48.5) 47.1 (41.2–53.3)
WN2 52.2 (46.1–57.2) 53.7 (46.3–58.8) 49.6 (41.5–55.4) 57.6 (51.2– 61.5) 57.1 (51.3–60.4)
WN3 56.4 (47.5–59.3) 56.4 (48.6–60.5) 59.7 (52.2–61.4) 66.1 (59.7– 71.4) 80.8 (79.2–88.3)a
WR 53.4 (45.8–58.2) 50.6 (42.4–56.3) 50.3 (41.8–56.1) 49.4 (42.5–55.7) 64.8 (59.8–69.5)
The WN3 model had the highest accuracy in predicting deep hypnotic state (MOAA/S = 0).
Abbreviations: CI, confidence interval; CNN, convolutional neural networks; MOAA/S, Modified Observer’s Assessment of Alertness/Sedation Scale; LSTM, 
long short-term memory; WN1, model trained on wake (W) and N1 sleep state; WN2, trained on W and N2 sleep state; WN3, trained on W and N3 sleep state; 
WR, trained on W and rapid eye movement (R) sleep state; M54, model tested to discriminate between MOAA/S = 5 and 4; M53, model tested to discriminate 
between MOAA/S = 5 and 3; M52, model tested to discriminate between MOAA/S = 5 and 2; M51, model tested to discriminate between MOAA/S = 5 and 1; 
M50, model tested to discriminate between MOAA/S = 5 and 0.
aHighest performance obtained by the model.
1218   www.anesthesia-analgesia.org ANESTHESIA & ANALGESIA
Hypnosis Level Prediction Using Deep Learning
power = 50 (47.2–54.1)%, and beta power = 52.7 (41.5–
61.4)%. When all spectral features were used together 
in the traditional linear discriminant analysis, support 
vector machine (linear kernel, box constraint = 1) and 
random forest (100 trees) models to predict deep hyp-
nosis, the system achieved an overall accuracy of 61.2 
(55.3–63.2), 70.5 (65.8–74.4), and 72.8 (67.2–78.3)%, 
respectively. This suggests that the traditional spectral 
analysis alone is not suitable to predict deep hypnosis 
during dexmedetomidine infusion.
DISCUSSION
Our study provides a novel data-repurposing frame-
work using DL and large-scale EEG data to track 
hypnotic levels from sleep brain rhythms. The LSTM-
CNN model predicted a deep hypnotic state with 
accuracy >80% when trained on the publicly available 
SHHS sleep data set and tested on the independent 
UMCG dexmedetomidine clinical trial data set. We 
also demonstrate using the DL algorithm that EEG 
patterns in dexmedetomidine-induced deep hypnotic 
state mimic NREM sleep stage 3 EEG patterns. To the 
best of our knowledge, this is the first study to explore 
the potential of DL algorithms to predict hypnotic lev-
els using sleep brain rhythms.
The classical approach to developing EEG-based 
hypnosis level tracking systems is to extract infor-
mation from frontal EEG channels mounted on the 
forehead to capture dynamic changes in the EEG oscil-
lations at different level of hypnosis. This requires 
expensive clinical trials to record and analyze EEG 
data, develop techniques to monitor hypnotic levels 
for each drug class. Another major limitation with such 
techniques is that they are dependent on feature engi-
neering and several potential discriminative features 
may not be included in the analysis. DL algorithms do 
not require any prior hand-crafted features and can 
learn potential discriminative features directly from 
the raw data. Our results suggest that DL algorithms, 
when trained on a sleep data set, can predict the hyp-
notic level and obtain nearly similar performance 
when trained on a dexmedetomidine data set (81% vs 
85%, P = .74), eliminating the need for clinical trials to 
develop hypnotic level monitors.
Several previous studies using traditional spec-
trogram analysis have shown that dexmedetomidine 
hypnotic EEG patterns are characterized by slow oscil-
lations in the slow-delta band (0–4 Hz) and spindle-
like activities in spindle band (12–16 Hz), similar to 
NREM sleep EEG patterns. Though it is evident that 
dexmedetomidine hypnotic EEG mimics NREM sleep 
EEG, it was unclear which NREM sleep stage (N2 or 
N3) is homologous with a deep hypnotic state. Oto et 
al28 demonstrated that nighttime infusion of dexme-
detomidine-induced hypnosis is synonymous with 
N2 sleep stage in 10 mechanically ventilated intensive 
care unit (ICU) patients. A study by Alexopoulou 
et al29 also demonstrated that dexmedetomidine infu-
sion increases N2 sleep stage in 13 ICU patients. In 
both these studies, continuous infusion of dexme-
detomidine was given targeting a light hypnosis level 
(Richmond Agitation-Sedation Scale between −1 and 
−4). A recent study by Akeju et al11 demonstrated that 
dexmedetomidine infusion significantly increased N3 
sleep stage in a dose-dependent manner when com-
pared to natural sleep in 10 healthy volunteers. Though 
intrasubject variability in these EEG patterns is mini-
mal, there is considerable intersubject variability (for 
both sleep and dexmedetomidine) due to factors such 
as sex,30 age,31,32 or genetic factors33,34; an example is 
shown in Figure 5. Using large-scale EEG data and DL, 
we demonstrate that dexmedetomidine-induced deep 
hypnotic level is synonymous to N3 sleep stage. This 
Figure 5. Spectrogram comparison of deep hypnosis and N3 sleep 
stage. Comparison of 5-min EEG power spectrogram from 4 subjects 
during (A) N3 sleep state in SHHS and (B) dexmedetomidine deep hyp-
notic state in UMCG. We can clearly see large variability in the slow-
wave delta band (0–4 Hz) and spindle band (11–16 Hz) across subjects 
in both SHHS and UMCG data set. The following values were set to 
perform spectral estimation using multitaper spectral estimation via 
the chronux toolbox: length of the window T = 4 s with 0.1 s shift, 
time-bandwidth product TW = 3, number of tapers K = 5, and spec-
tral resolution 2 W of 1.5 Hz. EEG indicates electroencephalogram; 
SHHS, Sleep Heart Health Study; TW, time-bandwidth product; UMCG, 
University Medical Center Groningen.
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kind of external validation, as proposed in this study, 
is important to capture heterogeneity commonly seen 
in EEG recordings.
It should be noted that though the DL model was 
trained on SHHS data set and later used to predict 
hypnosis level on the UMCG data set, the proposed 
data-repurposing framework should not be confused 
with the typical transfer learning problem. In transfer 
learning, the pretrained model from data set A is used 
as a starting model, retrained on data set B to perform 
a prediction task within data set B. However, in the 
proposed data-repurposing approach, we used exist-
ing data set (SHHS) that is used to answer clinical 
questions in 1 domain (in this case sleep staging) to 
answer clinical questions in another domain (hypno-
sis level prediction) on a different data set (UMCG). 
The DL algorithm was trained from scratch using 
the SHHS data set and is completely different from 
transfer learning. However, any model developed for 
1-dimensional (1D) physiological signal classifica-
tion can be used for this application. Because differ-
ent platforms are used to develop DL models (keras, 
python versions, architecture selection), it is difficult 
and requires substantial time and effort to imple-
ment. Because this was out of the scope of the current 
study, we did not perform transfer learning.
An automated approach to monitoring dexmedeto-
midine as proposed in this study is presumably well 
suited for patients in ICUs. These patients have comor-
bid conditions that, in principle, will significantly affect 
their sleep cycles which influence their EEG dynamics 
as a function of time. By training the DL model on large 
heterogeneous sleep EEG data capturing dynamic vari-
ations in the time-frequency properties of the EEG sig-
nal, it is possible to monitor deep hypnotic levels in the 
ICU. To implement the proposed framework in clini-
cal settings as a patient independent system, we first 
train the DL model on W and N3 EEG segments from 
all available sleep data. The raw EEG signal from a new 
patient will be used as an input to this trained model 
which will provide a continuous probability of being 
either conscious or deeply hypnotized once every 30 
seconds. This framework can also be used as a patient-
specific (or personalized) hypnosis level monitoring 
system where the model is retrained repeatedly with 
new incoming 30-second EEG segments for initial few 
hours and then calibrate it for the underlying patient 
using reinforcement learning. By this way, the EEG 
of hypnosis monitoring will be based on the dynamic 
changes in the EEG that adaptively update the DL 
model specific to the underlying patient.
Imbalanced data can severely bias the model pre-
diction results during both training and testing.35,36 
In our study, we balanced both training and testing 
data for 2 reasons: (1) straightforward interpretation 
of the model performance when compared with a 
random chance level accuracy (50%) and (2) consis-
tent metric during both training and testing. Since we 
used all epochs corresponding to hypnosis (MOSS/S 
scores 4, 3, 2, 1) and random epochs corresponding to 
awake state (MOAA/S score 0), the model takes into 
account both inter- and intrasubject variability of EEG 
patterns.
Though results obtained in this study are promis-
ing, several limitations need to be addressed in the 
future study. First, we only used 2 EEG channels 
(C4/A1 and C3/A2) since the SHHS data set only 
included these 2 channels. Investigating hypnotic 
effects on other regions of the brain can reveal new 
insights about the anesthetic hypnosis mechanism. 
Second, we used dexmedetomidine data set from 
healthy volunteers and the results obtained should be 
validated in EEG recordings from patients in the ICU 
or undergoing surgery. Third, we only performed a 
hypnotic level prediction using dexmedetomidine 
as a prototype drug. Further validation is required 
to test this hypothesis and, as a future study, we will 
assess the performance of the system in other hyp-
notic drugs. Fourth, several epochs were misclassi-
fied (Supplemental Digital Content, Figure 3, http://
links.lww.com/AA/D7) and we could not achieve a 
perfect prediction (100%). Because this is a proof-of-
concept study, we did not perform rigorous model 
selection for best prediction performance and the cur-
rent model is not yet ready for clinical deployment to 
predict individual patient’s sedation level. An ideal 
system should accurately predict awake and hypnotic 
state and we believe that with more data and complex 
DL models, it is possible to develop such system.
To summarize, we provide a novel data-repurpos-
ing framework to predict anesthetic drug-induced 
hypnotic levels using sleep EEG data, which can be 
useful in developing hypnosis level monitoring sys-
tems. We also show using a data-driven approach 
that dexmedetomidine-induced deep hypnotic state 
mimics NREM sleep stage 3 and demonstrates the 
feasibility of DL algorithms to validate and verify the 
robustness of clinical hypothesis using large-scale 
EEG data instead of visual assessments using tradi-
tional EEG spectrogram. We also demonstrate that 
the DL model developed from archived cases (“train-
ing data”) generally allows reliable monitoring of 
hypnosis levels in new patients whose data were not 
included during the training process, thus the system 
can be used “out of the box.” E
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